Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Zamanian, K. Kudelko, D. Miller, M. McGoon, R. Benza, P. Hassoun, M. Nicolls, L. Chung (Stanford, San Francisco, Rochester, Pittsburgh, Baltimore, Palo Alto, United States Of America). Change in diffusing capacity for carbon monoxide as a predictor of outcomes in connective tissue disease-associated pulmonary arterial hypertension: Analysis from the REVEAL registry. Eur Respir J 2012; 40: Suppl. 56, 3929

Member's Comments

No comment yet.

Related content which might interest you: Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 963-965 Year: 2014 Slope of exercise ventilation to carbon dioxide production in patients with pulmonary arterial hypertension, either primary or associated with connective tissue disease Source: Annual Congress 2008 - Pulmonary mechanics and gas exchange Year: 2008 Ventilatory inefficiency relative to oxygen uptake and carbon dioxide output are independent predictors of mortality in pulmonary arterial hypertension Source: Annual Congress 2013 –Respiratory physiology in health and disease Year: 2013 Diffusing capacity for carbon monoxide and mortality in patients with chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012 No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Diffusing capacity for carbon monoxide (DLco) may predict appearance of pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Cardiac function in idiopathic pulmonary arterial hypertension patients with a severely reduced diffusion capacity Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy Source: Annual Congress 2013 –Clinical exercise physiology Year: 2013 Does carbon monoxide diffusing capacity (DLCO) effect results of pulmonary rehabilitation? Source: International Congress 2015 – Latest insights into pulmonary rehabilitation Year: 2015 Carbon monoxide diffusing capacity (DLCO) in COVID-19 survivors versus idiopathic pulmonary fibrosis (IPF): the pathogenetic features Source: Virtual Congress 2021 – A multidisciplinary approach to pulmonary rehabilitation and management of chronic respiratory diseases Year: 2021 Pulmonary veno-occlusive disease Source: Eur Respir J 2009; 33: 189-200 Year: 2009 Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 944-950 Year: 2007 Exercise oxygen desaturation and DLCO: Are they correlated? Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 The diagnostic value of exhaled carbon monoxide and arterial carboxyhaemoglobin measurements in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 408s Year: 2006 Low DLCO in pulmonary vascular diseases Source: Virtual Congress 2021 – Pulmonary vascular diseases Year: 2021 Acute effects of oxygen on pulmonary hemodynamic can help in differentiation of pulmonary hypertension at patients with connective tissue diseases Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (5) 2001877; 10.1183/13993003.01877-2020 Year: 2021 Diffusing capacity of the lung for carbon monoxide: association with long-term outcomes after lung transplantation in a 20-year longitudinal study Source: Eur Respir J, 59 (1) 2003639; 10.1183/13993003.03639-2020 Year: 2022